Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification

Table 2 CMR findings

	Controls	SSc	P value
	N = 20	N = 19	P value
LVEDV indexed, mL/m²	77 ± 16	69 ± 11	0.08
LVESV indexed, mL/m²	21 ± 5	18 ± 5	0.06
LVEF, %	73 ± 5	74 ± 6	0.52
LV Mass indexed, g/m²	52 ± 11	51 ± 8	0.74
LA size, mm	28 ± 5	37 ± 6	<0.001
RVEDV indexed, mL/m²	85 ± 19	77 ± 12	0.32
RVESV indexed, mL/m²	28 ± 7	25 ± 7	0.06
RVEF, %	67 ± 4	67 ± 6	0.14
Mid SA circumferential strain	-18.6 ± 1.0	-16.8 ± 1.6	<0.001
Peak diastolic circumferential strain rate (s-1)	114 ± 16	83 ± 26	<0.001
Presence of LGE (%)	0	10 (53)	–
Volume fraction of LGE > 2SD (%)	0	4 (2-5)	–
Global myocardial T2 SI Ratio	1.6 ± 0.5	1.7 ± 0.4	0.66
Volume fraction of oedema by T2 (%)	0	13 (0-21)	–
Average myocardial T1, ms	958 ± 20	1007 ± 29	<0.001
Volume fraction of T1 > 990 ms (%)	3 (1-9)	52 (40-70)	<0.001
Postcontrast T1, ms	454 ± 29	457 ± 50	0.9
λ	0.44 ± 0.15	0.56 ± 0.23	0.02
ECV (%)	27.6 ± 2.5	35.4 ± 4.8	<0.001

Continuous data are mean ± SD unless otherwise indicated.
LA, Left atrium; LGE, Late gadolinium enhancement; LV, Left ventricle/ventricular; LVEDV, Left ventricular end-diastolic volume; LVEF, Left ventricular ejection fraction; LVESV, Left ventricular end-systolic volume; RVEDV; Right ventricular end-diastolic volume; RVEF, Right ventricular ejection fraction; RVESD, Right ventricular end-systolic volume; SA, Short axis; SSc, Systemic sclerosis; STIR, Short Tau inversion recovery.
For postcontrast T1, λ and ECV, the number of SSc patients included in the analysis is 14 rather than 19.

ISSN: 1532-429X